PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19858394-0	2009	VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.	Melphalan	17-26	neurensin 1	Homo sapiens	0-3	
24849305-7	2014	The combination of bortezomib, melphalan and prednisone (VMP) was shown to significantly improve overall survival (OS) compared to melphalan and prednisone (MP, 56.4 vs. 43.1 months, p = < 0.01).	Melphalan	31-40	neurensin 1	Homo sapiens	57-60	
31768675-3	2020	Thirty-six patients of median age 74 years old with NDMM initially received 35-day cycles of VMP: oral melphalan (6 mg/m2) and prednisolone (60 mg/m2) on days 1 to 4 and bortezomib (1.3 mg/m2) on days 1, 8, 15, and 22.	Melphalan	103-112	neurensin 1	Homo sapiens	93-96	
28906482-2	2017	Currently, VMP (bortezomib, melphalan, prednisone) is one of the standard regimens recommended as the first-line therapy for patients with MM ineligible for high-dose chemotherapy (HDT) with autologous stem-cell transplantation (auto-SCT).	Melphalan	28-37	neurensin 1	Homo sapiens	11-14